Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 254 (TMEM254)
- Target
- TMEM254
- Molecular classification
- Transmembrane protein, Integral membrane protein, Domain of unknown function (DUF4499), Other
01
Overview
Transmembrane protein 254 (TMEM254) is a small transmembrane protein predicted to contain five transmembrane domains and to localize to membranes, with highest expression in reproductive tissues, thyroid, kidney, skin, breast, and testes[1][7][12]. It consists of 147 amino acids and has a predicted molecular weight of about 16.4 kDa[1][12]. TMEM254 is highly conserved across eukaryotes but lacks known paralogs and has a protein domain classified as DUF4499, which is a “domain of unknown function”[1][2][6][12]. The biological function of TMEM254 remains uncharacterized, with no conclusive data on its involvement in cell signaling, metabolism, or other cellular pathways[2][4][6]. No drugs, biomarkers, or therapeutic safety considerations are currently linked to TMEM254, and while there are some genetic associations reported in population data, clinical or mechanistic significance is lacking[5][9].
- Other names
- C10orf57BA369J21.6 (or bA369J21.6)FLJ13263TM254_HUMAN (UniProt)GC10P081838 (GeneCards)Chromosome 10 open reading frame 57
02
Mechanism of action
Not applicable—no drugs are known to directly target this molecule
03
Biological functions
Unknown/Other Experimental studies have not clarified precise molecular or cellular functions. It is predicted to be an integral membrane protein, expressed in multiple tissues including reproductive organs, thyroid, pancreas, kidney, and skin.
04
Disease associations
Other No well-established disease associations. Some evidence links gene locus to late-onset Alzheimer’s disease and arrhythmogenic right ventricular cardiomyopathy, but roles are not functionally validated or clinically established.
05
Safety considerations
None known—no function as a drug target, biomarker, or disease gene; thus, no specific safety or therapeutic challenges are described.
06
Interacting drugs
None known. There are no established small-molecule or biologic drugs interacting with TMEM254.
07
Biomarkers
None known. TMEM254 is not established as a clinical biomarker for any disease or therapeutic response.
Beyond the preview
Go deeper on Transmembrane protein 254 (TMEM254).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane protein 254 (TMEM254).